Avadel Pharmaceuticals Enters into Exclusive Negotiations with Serenity Pharmaceuticals for NoctivaTM
(WorldNews Africa)

DUBLIN, Ireland, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) (`Avadel`), today announced that it has entered into an agreement for the right to exclusively negotiate with Serenity Pharmaceuticals, LLC (`Serenity`), for the sole rights to commercialize and further develop Noctiva in the United States and Canada. Noctiva is a proprietary low-dose formulation of, and delivery system for, the drug desmopressin acetate. It was specifically developed to meet the needs of nocturia patients and was approved by the U.S. Food and Drug Administration (`FDA`) on March 3, 2017. Noctiva is the first and only drug approved for the treatment of nocturia due to nocturnal...